Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00213876
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : August 30, 2011
Information provided by:
University Hospital, Strasbourg, France

Brief Summary:
At present, diagnosis of oligodendroglioma is made on histological and radiographic criteria in the French Mayo-Ste Anne classification. The less frequent grade A oligodendrogliomas are characterized by no vascular contrast on RMN evaluation comparatively to grade B forms. This benign histological subtype relapses in few cases with a more aggressive histology. To determine these relapsed cases at diagnosis, a collection of tumour begun in February 2004. Then, our study was designed to identify diagnostic molecular and metabolic markers that could eventually be used as a signature characterising grade A versus grade B oligodendrogliomas. The molecular analysis will use genomic techniques like allelotyping study, quantitative real-time PCR, gene sequencing , serial analysis of genomic expression and immunohistochemistry, since the metabolic study will be the spectroscopic examination of in vivo tumour. This study will include paediatric and adult patients followed for oligodendrogliomas, medulloblastomas and gliomas to compare the different tumour signatures. All these results will be correlated to survival and clinical features.

Condition or disease

Study Type : Observational
Actual Enrollment : 189 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively.
Study Start Date : February 2004
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient with oligodendroglioma or medulloblastoma or glioma

Inclusion Criteria:

  • Paediatric and adult patients (> 1 year of age)
  • Patient with oligodendroglioma or medulloblastoma or glioma
  • Possibility of 3 year follow-up
  • Patient consent obtained

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00213876

Natacha Entz-Werle
Strasbourg, France
Sponsors and Collaborators
University Hospital, Strasbourg, France
Principal Investigator: Natacha Entz-Werle, MD Hopitaux Universitaires de Strasbourg Identifier: NCT00213876     History of Changes
Other Study ID Numbers: 3154
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: August 30, 2011
Last Verified: August 2011

Keywords provided by University Hospital, Strasbourg, France:
Brain tumours
Presence of molecular abnormalities statistically linked to survival or response to chemotherapy

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue